MRNA vs NVDA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 06, 2026
MRNA
48.8
AI Score
VS
NVDA Wins
NVDA
55.6
AI Score
Investment Advisor Scores
NVDA
56score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | MRNA | NVDA | Winner |
|---|---|---|---|
| Revenue | 534.00M | 81.61B | NVDA |
| Net Income | -2.13B | 58.32B | NVDA |
| Net Margin | -397.9% | 71.5% | NVDA |
| Operating Income | -2.20B | 53.54B | NVDA |
| ROE | -31.4% | 29.8% | NVDA |
| ROA | -19.4% | 22.5% | NVDA |
| Total Assets | 10.96B | 259.47B | NVDA |
| Cash | 1.72B | 13.24B | NVDA |
| Debt/Equity | 0.09 | 0.04 | NVDA |
| Current Ratio | 2.29 | 3.44 | NVDA |
Relative Price Performance (Last 90 Days)
MRNA 1M: -22.7%
· 3M: +21.9%
NVDA 1M: +10.4%
· 3M: +5.9%
Current Technical Phase
MRNA
NeutralHold
Mixed signals - no dominant trend phase, RSI 50
NVDA
NeutralHold
Mixed signals - no dominant trend phase, RSI 65
Fundamentals Snapshot
| Metric | MRNA | NVDA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -11.0 | 28.5 |
| Trailing P/E | — | 33.5 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.9% |
| Gross Margin | -0.7% | 0.7% |
| Operating Margin | -5.6% | 0.7% |
| EPS | -7.88 | 6.53 |
| Dividend Yield | — | 0.00% |
Frequently Asked Questions
Based on our detailed analysis, NVDA is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.